How to appeal a Cigna glaucoma (drops + procedures + surgery) denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

Cigna-specific note: Sold its Medicaid Advantage book to HCSC in 2023. Express Scripts (PBM) is Cigna-owned. Frequent class-action litigation around mental health parity.

What Cigna's policy requires for glaucoma (drops + procedures + surgery)

Cited policy: Cigna Coverage Policy: Vyzulta (Latanoprostene Bunod 0.024%)

POAG or OHT meeting treatment threshold. Documented inadequate response, intolerance, or contraindication to generic latanoprost OR another preferred PGA. Quantity limit: 2.5 mL bottle q30d.

How Cigna denies glaucoma (drops + procedures + surgery) — and how to counter it

Where Cigna pushes back: 1) Step therapy: generic latanoprost first; 2) Vyzulta non-formulary.

Counter-arguments that hold up: Vyzulta (LBN) FDA-approved Nov 2 2017 — DUAL mechanism: latanoprost-acid uveoscleral outflow + butanediol mononitrate releasing nitric oxide for trabecular outflow (mechanism ABSENT in latanoprost monotherapy). APOLLO + LUNAR Phase 3 (Weinreb Am J Ophthalmol 2016) — LBN 0.024% non-inferior/superior to timolol; pooled vs latanoprost showed superior IOP reduction at multiple timepoints. Patient has documented latanoprost trial with inadequate response / intolerance / IOP above target. Generic latanoprost has uveoscleral mechanism only — Vyzulta adds NO-mediated trabecular pathway.

What Cigna typically denies for glaucoma (drops + procedures + surgery)

Across Cigna's commercial and Medicare books, denials cluster around a small number of patterns. For glaucoma (drops + procedures + surgery), expect:

• Mental health parity violations
• Step therapy
• Specialty drug prior auth
• OON balance billing disputes

Treatments most often denied in this category

These are the glaucoma (drops + procedures + surgery) treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Latanoprost (generic)
• Xelpros (BAK-free latanoprost)
• Travatan Z (travoprost)
• Lumigan (bimatoprost)
• Zioptan (tafluprost PF)
• Vyzulta (LBN)

How to submit the appeal to Cigna

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Cigna cited in the denial.
3. File the appeal through Cigna's portal (members: https://my.cigna.com ; providers: https://cignaforhcp.cigna.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In CT, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Cigna's prior-authorization criteria by drug: Cigna PA criteria on ApprovalHelp.